SCHEMBL4528112

SCHEMBL4528112

CC(=O)c1oc(N)nc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
LMNA P02545 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
IKBKB O14920 4/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
FBP1 P09467 6/20 0.35
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2714738 0.84 GABRP (0.39) HSD17B10KDM4EALDH1A1HPGDFBP1
SCHEMBL6802200 0.78 FBP1 (0.51) HSD17B10KDM4EALDH1A1HPGDLMNA
SCHEMBL16437815 0.76 SMN1; SMN2 (0.37) HSD17B10KDM4EALDH1A1HPGDLMNA
SCHEMBL781841 0.75 FBP1 (0.56) HSD17B10KDM4EALDH1A1HPGDLMNA
SCHEMBL5960474 0.74 SMN1; SMN2 (0.35) HSD17B10KDM4EALDH1A1HPGDLMNA
SCHEMBL5486555 0.71 HTT (0.38) HSD17B10SMN1; SMN2MAPT
SCHEMBL8616898 0.71 DDR1 (0.40) HSD17B10KDM4ESMN1; SMN2GAAMAPT
SCHEMBL19628643 0.71 PIK3CG (0.35) HSD17B10KDM4EALDH1A1HPGDLMNA
SCHEMBL4528040 0.69 ALDH1A1 (0.41) HSD17B10KDM4EALDH1A1HPGDLMNA
SCHEMBL8632441 0.68 IKBKB (0.50) IKBKBSMN1; SMN2FBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210369716-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES NOVARTIS AG (CH) 2021-12-02 US disclosed
CN-108863972-B Oxazole amide derivative and preparation method and application thereof 湖南大学 2020-08-04 CN disclosed
US-10596175-B2 Compounds and compositions for the treatment of parasitic diseases NOVARTIS AG (CH) 2020-03-24 US disclosed
US-20190000852-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2019-01-03 US disclosed
US-20170333437-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2017-11-23 US disclosed
US-20170333437-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2017-11-23 US disclosed
US-9700559-B2 Compounds and compositions for the treatment of parasitic diseases NOVARTIS AG (CH) 2017-07-11 US disclosed
US-9700559-B2 Compounds and compositions for the treatment of parasitic diseases NOVARTIS AG (CH) 2017-07-11 US disclosed
US-20160303129-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES NOVARTIS AG (CH) 2016-10-20 US disclosed
US-9303034-B2 Compounds and compositions for the treatment of parasitic diseases NOVARTIS AG (CH) 2016-04-05 US disclosed
US-9150561-B2 Thiazole derivatives and use thereof MERCK SERONO S.A. (CH) 2015-10-06 US disclosed
US-20150175613-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES IRM LLC (BM) 2015-06-25 US disclosed
US-20140274926-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES IRM LLC (BM) 2014-09-18 US disclosed
US-20140275119-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES NOVARTIS AG (CH) 2014-09-18 US disclosed
US-20140228365-A1 THIAZOLE DERIVATIVES AND USE THEREOF MERCK SERONO S.A. (CH) 2014-08-14 US disclosed
US-8802861-B2 Thiazole derivatives and use thereof MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-20090029998-A1 Thiazole Derivatives and Use Thereof APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) 2009-01-29 US disclosed
EP-1709019-B1 THIAZOLE DERIVATIVES AND USE THEREOF APPLIED RESEARCH SYSTEMS (AN) 2007-08-08 EP disclosed
EP-1709019-A2 THIAZOLE DERIVATIVES AND USE THEREOF Applied Research Systems ARS Holding N.V. (AN) 2006-10-11 EP disclosed
WO-2005068444-A2 THIAZOLE DERIVATIVES AND USE THEREOF APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2005-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150175613-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES TYR, TBCA, MAPT HSD17B10 800/4885KDM4E 3178/4885ALDH1A1 866/4885
US-20140228365-A1 THIAZOLE DERIVATIVES AND USE THEREOF PF4, TEC, PDGFRB HSD17B10 3061/4885KDM4E 4820/4885ALDH1A1 234/4885
US-20140274926-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES TYR, TBCA, MAPT HSD17B10 805/4885KDM4E 3172/4885ALDH1A1 816/4885
US-20190000852-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES TYR, TBCA, MAPT HSD17B10 800/4885KDM4E 3178/4885ALDH1A1 866/4885
US-20140275119-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES TYR, TBCA, MAPT HSD17B10 805/4885KDM4E 3172/4885ALDH1A1 816/4885
US-10596175-B2 Compounds and compositions for the treatment of parasitic diseases TYR, TBCA, MAPT HSD17B10 800/4885KDM4E 3178/4885ALDH1A1 866/4885
US-20090029998-A1 Thiazole Derivatives and Use Thereof PDGFRB, PDGFRA, TEC HSD17B10 2663/4885KDM4E 4801/4885ALDH1A1 174/4885
US-20160303129-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES TYR, TBCA, MAPT HSD17B10 800/4885KDM4E 3178/4885ALDH1A1 866/4885
US-20210369716-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES TYR, TBCA, MAPT HSD17B10 800/4885KDM4E 3178/4885ALDH1A1 866/4885
US-20170333437-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES TYR, TBCA, MAPT HSD17B10 800/4885KDM4E 3178/4885ALDH1A1 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.